Introduction
Fibronectins (FNs) have critical roles in cell adhesion, migration, differentiation and proliferation via their interactions with integrins and other cell surface receptors. These large glycoproteins are found either in plasma as soluble proteins or in the extracellular matrix in their insoluble form.
Extensive studies have shown that loss of FN is a common concomitant of transformation (1) , and several reports have indicated that the repression of FN function during neoplastic transformation occurs at the transcriptional level (2) (3) (4) . Accordingly, Werbajh et al identified a 220-bp proximal promoter region involved in the repression of FN expression (5) . The proximal region of the rat FN promoter contains a cyclic AMP response element (CRE) at position -160, a G10 stretch at position -239 and GC boxes at positions -105 and -54, relative to the transcription start site (4). Oda et al reported that repression of the FN gene during G1-to-S progression is mediated by G10BP, which binds to the G-rich sequences in the FN promoter and prevents SP1 from binding to these sites (6) .
We previously showed that the human papillomavirus type 16 E6 (HPV16-E6) protein transcriptionally activates FN, and that modulation of FN expression occurs by E6-induction of binding to the -160 CRE site by a complex containing c-Jun (7) . As c-Jun exhibits oncogenic potential to transform cells alone or in the presence of a cooperating oncogene (8) (9) (10) (11) , transactivation of the FN gene via c-Jun appeared contradictory.
In this study, we examined the mechanism by which c-Jun regulates FN gene expression. Here, we report that overexpression of c-Jun transcriptionally represses FN gene expression via the -160 CRE, and that ATF-2 may be required in the protein complexes bound to CRE for HPV16-E6-mediated transactivation of FN.
Materials and methods
Cells. The 10T/2 mouse cell line was maintained in RPMI-1640 medium containing 10% fetal calf serum (FCS). Cell lines expressing c-Jun were established by transfection of the pRc/CMV2-c-Jun expression plasmid into 10T1/2 cells and subsequent selection with G418. The c-Jun-expressing cell lines and a 10T2/1 cell line stably expressing HPV16-E6, 10E6-3 (12), were maintained in RPMI-1640 medium containing 10% FCS and G418 (400 μg/ml).
Plasmids. pF166Luc, pF123Luc and pF166mLuc were constructed by the HindIII-BglII digestion of rat FN promoter-CAT fusion plasmids, pF166CAT, pF123CAT and pF166mCAT (7), respectively, and the subsequent ligation of the HindIII-BglII fragments into the pGL3-Basic luciferase expression vector (Promega, Madison, WI, USA). To construct the pRc/CMV2-c-Jun expression plasmid, pCMV-c-Jun was digested with EcoRI-BamHI, and the fragment containing mouse c-Jun was ligated into XbaI-HindIII-digested pRc/ CMV2. pCMV-c-Jun and the TAM-67 expression plasmid pCMV-67 were gifts from Michael J. Birrer (13) .
Antibodies. Anti-c-Jun, anti-fibronectin, anti-fos, anti-CREB and anti-ATF2 antibodies were purchased from Santa Cruz c-Jun-mediated repression and transactivation of fibronectin YUKIO (14) . mRNA expression levels were quantified using a BAS 2500 Bioimaging analyzer (Fujix, Japan).
Western blot analysis. Cell extracts were mixed with a buffer containing 25 mmol/Tris-HCl, 1% sodium dodecyl sulfate (SDS), 5% glycerol, 1% 2-mercaptoethanol and 0.1% bromophenol blue, and boiled for 5 min. The samples were resolved on 12.5% SDS polyacrylamide gels and transferred electrophoretically onto filters (Immobillon, Millipore, Bedford, MA). The membranes were treated with 10% non-fat dry milk in PBS containing 0.01% Tween-20 (PBS-T) and incubated with anti-c-Jun, anti-fibronectin or anti-ATF-2 antibody for 6 h at 4˚C. Blots were washed with PBS-T, incubated with horseradish peroxidase-conjugated secondary antibody for 1 h, processed with the ECL Plus Detection Kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) and exposed to film.
Luciferase reporter assays. Cells were transfected with 5 μg of luciferase reporter plasmid mixed with 1 μg of the pRL-SV40 internal marker (Promega). After 48 h, cells were washed twice with PBS, collected by scraping and freeze-thawed three times. The lysates were analyzed for luciferase activity with a Wallac 1420 ARVOsx (Perkin Elmer) using the Dualluciferase assay (Promega), according to the manufacturer's instructions. Experiments were repeated three times.
Recombinant adenovirus. Adex16E6 is a recombinant adenovirus that expresses HPV16-E6 (nt. 94-571) without the splice donor site (15, 16) . For transient expression of HPV16-E6, cells were infected with Adex16E6 at an MOI of 100.
Nuclear extracts and gel retardation assays. Nuclear extracts were prepared from rapidly growing subconfluent cultures as described previously (7) . All extracts were standardized for protein concentration before use. The 32 P-labeled DNA fragment used as a probe was obtained by Klenow enzyme filling with [α-32 P]dATP. Binding reactions were carried out in 20-μl reaction volumes as described previously (7). For antibody supershift assays, specific polyclonal antibodies to c-Jun, ATF-2, CREB or Fos, were added to the binding reaction mixture prior to the addition of the labeled oligo-nucleotide for 2 h at 4˚C. Binding reaction mixtures were incubated for 30 min at room temperature. DNA-protein complexes were separated from unbound DNA by electrophoresis in 5% polyacrylamide gels.
Results

Induction of c-Jun by HPV16-E6.
We previously showed that HPV16-E6 protein transcriptionally modulates FN gene expression via CRE by inducing the binding of protein complexes consisting of c-Jun and ATF-2 to CRE sites (7) . To further investigate the role of c-Jun in FN gene expression, we first examined the effect of HPV16-E6 on the expression level of c-Jun. Consistent with previous findings, FN mRNA expression in the HPV16-E6-expressing 10E6-3 mouse cell line was enhanced compared to the 10T1/2 parental cell line (Fig. 1A) . Notably, both c-Jun mRNA and c-Jun protein were highly expressed in 10E6-3 cells compared to control cells. To test if c-Jun is transactivated by HPV16-E6, 10T1/2 cells were infected with the recombinant Adex16E6 adenovirus, which expresses HPV16-E6 (16) . As shown in Fig. 1B , the expression (Fig. 2A) . Consistent with results from the mRNA analysis, the downregulation of FN protein expression and the enhancement of c-Jun protein expression in the c-Jun-overexpressing 10J-17 cells compared to the parental 10T1/2 cells was confirmed (Fig. 2B) .
Repression of the FN promoter by overexpression of c-Jun.
To examine whether the decreased level of FN occurs at the transcriptional level, 10J-17 and 10T1/2 cells were transfected with pF166Luc luciferase reporter driven by FN promoter (Fig. 3A) . Luciferase activity in 10J-17 cells was only 5% relative to that of the 10T1/2 cells, indicating a strong repression of FN promoter activity and suggesting that repression of FN gene expression occurs at the transcriptional level in c-Jun-overexpressing 10J-17 cells (Fig. 3B) .
To confirm whether c-Jun represses the FN promoter, 10T1/2 cells were co-transfected with pF166Luc and increasing amounts of the pCMV-c-Jun expression plasmid, and luciferase activity was assessed. The transient expression of c-Jun efficiently repressed the activity of pF166Luc; notably, no effect was observed using pF123Luc lacking CRE at -160 (Fig. 3C) , suggesting that -160 CRE is necessary for c-Junmediated repression of the FN promoter.
TAM-67, a deletion mutant of c-Jun lacking the transactivation domain and retaining DNA binding activity, competes and inhibits c-Jun transcriptional activation by preventing wildtype c-Jun from binding to CRE (13) . To examine the effect of TAM-67 on the activity of the FN promoter, pF166Luc was co-transfected into 10T1/2 cells along with the TAM-67 expression plasmid pCMV-67. Under these conditions, a dose-dependent increase in luciferase activity was observed (Fig. 3D) and mutation of the CRE site (pF166mLuc) abolished the effects of pCMV-67.
Complexes binding to CRE in c-Jun-expressing cells.
In a previous study (7), we showed that nuclear extracts from the 10E6-3 E6-expressing mouse cells exhibited greater DNA binding activity of protein complexes to the CRE site, and that these complexes contained c-Jun and ATF-2. To confirm that transiently expressed E6 promotes c-Jun/ATF-2 DNA binding to the consensus CRE site, whole cell extracts from 10T1/2 cells infected with Adex16E6 were examined for DNA binding activity. As shown in Fig. 4A , the CRE-protein complex band was supershifted by the anti-c-Jun antibody, while the anti-ATF-2 antibody reduced binding dramatically (~3-fold reduction in band intensity); the bands were neither supershifted nor disrupted by either the anti-c-Fos or anti-CREB antibodies. However, in 10J-17 cells that overexpressed c-Jun and lacked HPV16-E6 expression, the DNA-protein complex was supershifted by anti-c-Jun but not disrupted by the anti-ATF2 antibody (Fig. 4B) , indicating that the CREbound protein complexes lacked ATF-2. Immunoblot analyses showed that ATF-2 expression was observed in 10E6-3 but not 10J-17 cells (Fig. 4C) , supporting the absence of ATF-2 in the CRE-bound protein complexes of 10J-17 cells.
Discussion
Our study demonstrated that c-Jun both transactivates and represses FN gene expression depending on the cellular context. Decreased FN production is often observed following oncogenic transformation, leading to decreased adhesion and increased metastatic potential (1, 5) . Conversely, restoration of FN expression has been shown to revert tumorigenic and/or metastatic phenotypes (17) . However, it has also been reported that FN gene expression is upregulated in transformed cells by several oncoproteins (18, 19) .
The human FN promoter contains three CREs, one of which is bound by the c-Jun-ATF-2 heterodimer. TGF-ß mediates FN synthesis by modulating the activity of c-Jun-ATF-2 via the CRE of the FN promoter (20) . In a previous report, we demonstrated that the oncoprotein HPV16-E6 transactivates the FN gene, inducing the binding activity of c-Jun-ATF-2 complexes to CRE (7). The current study suggests that the FN gene repression often observed in cancer cells could be modulated or de-repressed depending on the cellular context through the course of tumor progression.
This study also revealed that HPV16-E6 not only transactivates FN gene expression, but also c-Jun expression. Furthermore, the overexpression of c-Jun in the absence of HPV16-E6 expression repressed FN gene expression. Downregulation of FN gene expression in c-Jun-overexpressing cells, in which CRE-bound protein complexes lacked ATF-2, indicated that ATF-2 expression and CRE binding could be required for the transactivation of FN gene expression.
Transactivation of the FN gene by the dominant-negative c-Jun TAM-67 in 10T1/2 cells that express low levels of ATF-2 suggested that c-Jun complexes lacking ATF-2 can mediate repression. In our study, upregulation of the FN gene by TAM-67 could possibly be due to TAM-67 releasing the endogenous c-Jun-mediated repression.
The protein complexes involved in the repression of the FN gene could be mediated by either c-Jun homodimers or c-Jun heterodimers with unknown factors besides ATF-2. Our study suggests that the same transcription regulatory sequence could tightly regulate both the transactivation and repression of FN, depending on the cellular context. This hypothesis would explain the complicated expression pattern of the FN gene in cancer cells, and understanding the molecular mechanism by which the regulation of FN is disrupted and expression is repressed during tumorigenesis warrants further investigation.
